SCHEMBL3010505

SCHEMBL3010505

COc1ccc(Sc2ncc(Sc3nnc[nH]3)nc2C(=O)Nc2cnccn2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.42
KDM4E B2RXH2 1/20 0.42
GCK P35557 6/20 0.39
MAPT P10636 3/20 0.37
CYP2C19 P33261 1/20 0.37
CHRNB2 P17787 1/20 0.37
CHRNB4 P30926 1/20 0.37
CHRNA3 P32297 1/20 0.37
CHRNA4 P43681 1/20 0.37
SMN1; SMN2 Q16637 4/20 0.36
HTT P42858 3/20 0.36
RAB9A P51151 3/20 0.35
TP53 P04637 3/20 0.35
MEN1 O00255 2/20 0.35
NPC1 O15118 2/20 0.35
KMT2A Q03164 2/20 0.35
USP2 O75604 1/20 0.35
ALDH1A1 P00352 3/20 0.35
LMNA P02545 1/20 0.35
HSP90AA1 P07900 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3004132 0.91 RAB9A (0.35) KDM4EMAPTCYP2C19CHRNB2CHRNB4
SCHEMBL3013488 0.89 KMT2A (0.40) KDM4EGCKMAPTCYP2C19SMN1; SMN2
SCHEMBL3006784 0.86 POLB (0.42) POLBKDM4EGCKMAPTCYP2C19
SCHEMBL3002294 0.86 POLB (0.42) POLBKDM4EGCKMAPTCYP2C19
SCHEMBL2997075 0.85 HPGDS (0.45) GCKHTTRAB9AMEN1NPC1
SCHEMBL3008721 0.84 HPGDS (0.45) GCKHTTRAB9AMEN1NPC1
SCHEMBL3014587 0.82 GCK (0.43) KDM4EGCKMAPTSMN1; SMN2RAB9A
SCHEMBL2663244 0.78 GCK (0.41) GCKCHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL2994480 0.78 HPGDS (0.43) KDM4EGCKSMN1; SMN2RAB9ATP53
SCHEMBL2213471 0.77 GCK (0.53) GCKMAPTSMN1; SMN2RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100190980-A1 PYRAZINAMIDE COMPOUND TAISHO PHARMACEUTICAL CO., LTD (JP) 2010-07-29 US claimed
EP-2157090-A1 PYRAZINAMIDE COMPOUND Taisho Pharmaceutical Co. Ltd. (JP) 2010-02-24 EP claimed
US-20100190980-A1 PYRAZINAMIDE COMPOUND TAISHO PHARMACEUTICAL CO., LTD (JP) 2010-07-29 US disclosed
EP-2157090-A1 PYRAZINAMIDE COMPOUND Taisho Pharmaceutical Co. Ltd. (JP) 2010-02-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190980-A1 PYRAZINAMIDE COMPOUND KAT8, GK, KCNJ8 POLB 2632/4885KDM4E 1952/4885GCK 25/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.